Next 10 |
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , May 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and dev...
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study PR Newswire Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024 , at 9:51 AM CDT The abstract summary wil...
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer PR Newswire Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on...
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...
2024-03-12 09:29:51 ET More on Ideaya, Merck, etc. Merck & Co., Inc. (MRK) Management presents at Leerink Partners 2024 Global Biopharma Conference (Transcript) Merck & Co., Inc. (MRK) TD Cowen 44th Annual Healthcare Conference (Transcript) Merck: A Great Div...
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire Trial will evaluate IDE161, IDEAYA's investigational PARG inhibitor, in combination with KEYTRUDA ® ...
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
2024-03-08 12:11:45 ET More on IDEAYA, Immunocore, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Ideaya Biosciences: A Strong Bet In Targeted Oncology Immunocore Holdings: Vulnerable To Profit Taking After Big Rally Immunocore to work w...
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events PR Newswire SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development ...
2024-03-02 18:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , May 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and dev...
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study PR Newswire Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024 , at 9:51 AM CDT The abstract summary wil...
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer PR Newswire Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on...